You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
益方生物(688382.SH):KRASG12C抑制劑D-1553的臨牀研究成果入選2022年世界肺癌大會(WCLC2022)報吿
格隆匯 08-07 17:18

格隆匯8月7日丨益方生物(688382.SH)公佈,近日,公司自主研發的小分子KRASG12C抑制劑D-1553的臨牀研究成果入選2022年世界肺癌大會(WCLC2022)報吿,該研究的主要研究者上海市胸科醫院的陸舜教授於該大會期間就D1553的臨牀數據作口頭報吿。

KRAS信號傳導在細胞生長及存活中非常重要,KRAS突變陽性廣泛存在於多個高致死率癌種中,約有30%的非小細胞肺癌患者,約有40%-50%的結直腸癌患者及80%-90%的胰腺癌患者存在KRAS突變陽性。G12C是KRAS最常見的突變之一,目前在全球範圍內針對KRASG12C突變的創新藥物僅有安進的Sotorasib(AMG510)於2021年5月獲美國FDA有條件批准上市,用於治療既往至少接受過一次系統治療的攜帶KRASG12C突變局部晚期或轉移性非小細胞肺癌(NSCLC)患者。

目前,國內尚未有KRASG12C抑制劑獲批,KRASG12C突變的實體瘤目前也暫無標準治療方案。在KRASG12C抑制劑獲批上市之前,存在KRASG12C突變的非小細胞肺癌(NSCLC)患者的治療方案以化療及免疫治療為主,但由於上述治療不直接針對KRASG12C靶點,治療效果較為有限,因此KRASG12C突變的非小細胞肺癌(NSCLC)患者對KRASG12C抑制劑有着迫切的需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account